A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

NCT02493738 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Superficial Mycoses
Dermatomycoses
Candidiasis
Histoplasmosis

Interventions

DRUG: Lozanoc 50mg
DRUG: Sporanox 100mg

Sponsor

Boryung Pharmaceutical Co., Ltd